Jump to content
Sclero Forums
Jeannie McClelland

arGentis Receives Favorable Opinion in Europe

Recommended Posts

http://www.businesswire.com/portal/site/go...amp;newsLang=en. arGentis Pharmaceuticals, LLC announced today that the European Medicines Agency's(EMEA) Committee for Orphan Medicinal Products (COMP) adopted a positive opinion recommending the company’s product candidate ARG201 (native type 1 bovine collagen) for the treatment of diffuse systemic sclerosis, also known as systemic scleroderma (SSc) for designation as an orphan medicinal product to the European Commission. arGentis Pharmaceuticals. 01/06/09. (See also: Scleroderma Treatments)


This item was posted in the ISN Newsroom. Check the Newsroom every day for the latest scleroderma medical and support information.

Jeannie McClelland

(Retired) ISN Director of Support Services

(Retired) ISN Sclero Forums Manager

(Retired) ISN Blog Manager

(Retired) ISN Assistant News Guide

(Retired) ISN Artist

International Scleroderma Network

Share this post

Link to post
Share on other sites

Create an account or sign in to comment

You need to be a member in order to leave a comment

Create an account

Sign up for a new account in our community. It's easy!

Register a new account

Sign in

Already have an account? Sign in here.

Sign In Now